Cargando…
ALK阳性非小细胞肺癌靶向治疗研究进展
The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000407/ https://www.ncbi.nlm.nih.gov/pubmed/25539610 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05 |